跳至主要内容
临床试验/JPRN-jRCT1080225227
JPRN-jRCT1080225227已完成1 期

Randomized, placebo-controlled, double-blind, single-centre, Phase 1 trial to investigate tolerability, safety, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of SCO-094 subcutaneously administered in patients with type 2 diabetes

SCOHIA PHARMA, Inc.0 个研究点目标入组 68 人开始时间: 2020年6月11日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
68

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 18age old 至 <= 85age old(—)
性别
All

入选标准

  • Type 2 diabetic Caucasian male or females will be included if they are aged between 18 and 65 (inclusive), with a body mass index (BMI) between 18.0 and 35.0 kg/m2.
  • Patients must be stable and treated with either diet and exercise alone or an anti-glycaemic monotherapy (metformin, DPP-4i, pioglitazone, an SU or an SGLT-2i). Patients must agree to use effective methods of contraception.

排除标准

  • Patients treated with insulin such as type 1 diabetes or evidence of C-peptide deficiency and patients with
  • current or recurrent disease; e.g., cardiovascular, haematological, neurological, endocrine, immunological, renal, hepatic or gastrointestinal or other conditions)
  • that could affect the action, absorption, or disposition of SCO-094, or could affect clinical assessments or clinical laboratory evaluations.

研究者

相似试验

Safety, tolerability, PK and PD of SCO-094 in type 2... | 临床试验